WO2001030325A3 - Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients - Google Patents

Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients Download PDF

Info

Publication number
WO2001030325A3
WO2001030325A3 PCT/CA2000/001258 CA0001258W WO0130325A3 WO 2001030325 A3 WO2001030325 A3 WO 2001030325A3 CA 0001258 W CA0001258 W CA 0001258W WO 0130325 A3 WO0130325 A3 WO 0130325A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
treatment
peroxovanadium
bis
bpv
Prior art date
Application number
PCT/CA2000/001258
Other languages
French (fr)
Other versions
WO2001030325A2 (en
Inventor
Michel J Tremblay
Benoit Barbeau
Jean-Francois Fortin
Original Assignee
Virocell Inc
Michel J Tremblay
Benoit Barbeau
Fortin Jean Francois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virocell Inc, Michel J Tremblay, Benoit Barbeau, Fortin Jean Francois filed Critical Virocell Inc
Priority to CA002389348A priority Critical patent/CA2389348A1/en
Priority to EP00971189A priority patent/EP1225891A2/en
Priority to AU10141/01A priority patent/AU1014101A/en
Publication of WO2001030325A2 publication Critical patent/WO2001030325A2/en
Publication of WO2001030325A3 publication Critical patent/WO2001030325A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for restoring the immune functions and the overall immune response by administration of a bis-peroxovanadium (bpV) compound, a potent class of phosphotyrosyl phosphatase inhibitors. The method can be utilized in treating individuals afflicted with immune disorders or for the treatment of patients suffering from infections caused by viruses that destroy the natural immune response, such as the human immunodeficiency virus (HIV). The bpV compound may be used in combination with various immunomodulators and/or antiviral agents. The present invention also relates to the use of such bpV compound for restoring the immune functions and the overall immune response in a patient in need of such a treatment.
PCT/CA2000/001258 1999-10-26 2000-10-23 Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients WO2001030325A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002389348A CA2389348A1 (en) 1999-10-26 2000-10-23 Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients
EP00971189A EP1225891A2 (en) 1999-10-26 2000-10-23 Use of a bis-peroxovanadium compound for the treatment of immunosupressed patients
AU10141/01A AU1014101A (en) 1999-10-26 2000-10-23 Use of a phosphotyrosyl phosphatase inhibitor for the treatment of immunosuppressed patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16135499P 1999-10-26 1999-10-26
US60/161,354 1999-10-26

Publications (2)

Publication Number Publication Date
WO2001030325A2 WO2001030325A2 (en) 2001-05-03
WO2001030325A3 true WO2001030325A3 (en) 2002-01-24

Family

ID=22580857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001258 WO2001030325A2 (en) 1999-10-26 2000-10-23 Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients

Country Status (4)

Country Link
EP (1) EP1225891A2 (en)
AU (1) AU1014101A (en)
CA (1) CA2389348A1 (en)
WO (1) WO2001030325A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009677A2 (en) * 2000-08-02 2002-02-07 Virocell Inc. Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
EP1383792A2 (en) 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Sh2 domain binding inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000236A1 (en) * 1986-07-03 1988-01-14 Tompkins Wayne A F Methods and materials for vanadium immunomodulation
DE4336642A1 (en) * 1993-10-22 1995-04-27 Deutsches Rheuma Forschungszen Use of vanadium compounds for the production of pharmaceuticals with an antiviral action
WO1995020390A1 (en) * 1994-01-31 1995-08-03 Bristol-Myers Squibb Company Use of vanadium molybdenum or tungsten complexes for controlling cellular proliferation
WO2001012180A2 (en) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000236A1 (en) * 1986-07-03 1988-01-14 Tompkins Wayne A F Methods and materials for vanadium immunomodulation
DE4336642A1 (en) * 1993-10-22 1995-04-27 Deutsches Rheuma Forschungszen Use of vanadium compounds for the production of pharmaceuticals with an antiviral action
WO1995020390A1 (en) * 1994-01-31 1995-08-03 Bristol-Myers Squibb Company Use of vanadium molybdenum or tungsten complexes for controlling cellular proliferation
WO2001012180A2 (en) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARBEAU B ET AL: "Activation of HIV - 1 long terminal repeat transcription and virus replication via NF-kappaB-dependent and -independent pathways b potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 MAY 16) 272 (20) 12968-77., XP001034307 *
FORTIN J F ET AL: "Regulation of nuclear factor of activated T cells by phosphotyrosyl-specific phosphatase activity: a positive effect on HIV - 1 long terminal repeat-driven transcription and a possible implication of SHP-1.", BLOOD, (2001 APR 15) 97 (8) 2390-400., XP001030797 *
OLIVIER E A M: "Modulation of Interferon-gamma-induced macrophage activation by phosphotyrosine phosphatases inhibition", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 22, 1998, pages 13944 - 13949, XP002160782, ISSN: 0021-9258 *
OLIVIER M ET AL: "PV-MEDIATED PROTECTION AGAINST LEISHMANIASIS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, no. SUPPL, 1999, pages 31, XP000982208, ISSN: 0741-5400 *
OUELLET M ET AL: "p56(lck), ZAP-70, SLP-76, and calcium-regulated effectors are involved in NF-kappaB activation by bisperoxovanadium phosphotyrosyl phosphatase inhibitors in human T cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 DEC 3) 274 (49) 35029-36., XP001034306 *

Also Published As

Publication number Publication date
CA2389348A1 (en) 2001-05-03
WO2001030325A2 (en) 2001-05-03
EP1225891A2 (en) 2002-07-31
AU1014101A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
DE69738535D1 (en) ANTIVIRAL AGENTS FROM PLANT EXTRACTS AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
HUP0001379A2 (en) Antimicrobial prevention and treatment of human immunedeficiency virus and other virus infections
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
ATE238998T1 (en) SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORES
ATE245444T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS
DE602005016552D1 (en) PARAPOCK VIRUS IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV / AIDS
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
WO2001030325A3 (en) Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients
Heymann et al. Strategies for AIDS prevention and control in sub-Saharan Africa
ATE152717T1 (en) NAPHTOQUINONE COMPOUNDS, COMPOSITIONS AND USES ACTIVE AGAINST VIRUSES
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
UA41338C2 (en) Method for inhibiting retroviral infection caused by human immunodeficiency virus (hiv), method for inhibiting human immunodeficiency virus (hiv)
WO2005030149A3 (en) Suppression of hiv replication for prevention and treatment of hiv
DK1143976T3 (en) Beta-D-2 ', 3'-didehydro-2', 3'-dideoxy-5-fluorocytidine for use in the treatment of HIV infections
WO2002009677A3 (en) Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
AU2396900A (en) Treatment and prevention of hiv and other viral infections
Nash Congress Takes Holiday While Zika Spreads and Kills
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
Gonslaves Throw down your crutches and walk
WO2004108128A1 (en) The use of bullatacin in manufacturing the medicaments of suppressing aids virus
Scheibel Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2389348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000971189

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000971189

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000971189

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP